CN110996914A - 固定剂量制剂 - Google Patents

固定剂量制剂 Download PDF

Info

Publication number
CN110996914A
CN110996914A CN201880049937.4A CN201880049937A CN110996914A CN 110996914 A CN110996914 A CN 110996914A CN 201880049937 A CN201880049937 A CN 201880049937A CN 110996914 A CN110996914 A CN 110996914A
Authority
CN
China
Prior art keywords
composition
ezetimibe
bempedoic acid
tablet
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880049937.4A
Other languages
English (en)
Chinese (zh)
Inventor
默罕默德·阿卜杜纳赛尔
普拉蒂巴·S·皮尔冈卡尔
阿尼库马尔·甘德希
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esperion Therapeutics Inc
Original Assignee
Esperion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esperion Therapeutics Inc filed Critical Esperion Therapeutics Inc
Publication of CN110996914A publication Critical patent/CN110996914A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201880049937.4A 2017-05-26 2018-05-25 固定剂量制剂 Pending CN110996914A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762511889P 2017-05-26 2017-05-26
US62/511,889 2017-05-26
US15/859,279 US20180338922A1 (en) 2017-05-26 2017-12-29 Fixed dose formulations
US15/859,279 2017-12-29
PCT/US2018/034646 WO2018218147A1 (en) 2017-05-26 2018-05-25 Fixed dose formulations

Publications (1)

Publication Number Publication Date
CN110996914A true CN110996914A (zh) 2020-04-10

Family

ID=62621055

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880049937.4A Pending CN110996914A (zh) 2017-05-26 2018-05-25 固定剂量制剂

Country Status (15)

Country Link
US (2) US20180338922A1 (https=)
EP (1) EP3630070A1 (https=)
JP (3) JP7187488B2 (https=)
KR (3) KR20250109242A (https=)
CN (1) CN110996914A (https=)
AU (2) AU2018272040A1 (https=)
BR (1) BR112019024747A2 (https=)
CA (1) CA3064895A1 (https=)
CL (1) CL2019003437A1 (https=)
IL (2) IL270866B2 (https=)
MX (2) MX2019014122A (https=)
PH (1) PH12019502782A1 (https=)
TW (1) TWI798228B (https=)
UA (1) UA126451C2 (https=)
WO (1) WO2018218147A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111559961A (zh) * 2020-05-26 2020-08-21 杭州科巢生物科技有限公司 一种贝派地酸晶型及其制备方法

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3267989A4 (en) 2015-03-13 2018-11-07 Esperion Therapeutics, Inc. Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
AU2019221765A1 (en) * 2018-02-16 2020-09-10 Esperion Therapeutics, Inc. Sustained release formulations of bempedoic acid
US20210322375A1 (en) * 2018-08-27 2021-10-21 Esperion Therapeutics, Inc. Combination drug formulations for treating patients with cardiovascular disease and associated conditions
EP3666750A1 (en) * 2018-12-10 2020-06-17 Sandoz AG Crystalline form of bempedoic acid
WO2020213010A1 (en) * 2019-04-16 2020-10-22 Celagenex Research (India) Pvt. Ltd. Synergistic lipid controlling compositions
MX2021015936A (es) 2019-06-21 2022-04-26 Esperion Therapeutics Inc Metodos para preparar acido bempedoico y composiciones del mismo.
US12528759B2 (en) 2019-10-03 2026-01-20 Synthon B.V. Crystalline forms of bempedoic acid
US12516013B2 (en) 2019-12-06 2026-01-06 Synthon B.V. Crystalline forms of sodium salt of Bempedoic acid
CN115379861A (zh) * 2020-04-10 2022-11-22 日本瓦姆&珀巴尔株式会社 缓释性主剂
WO2021220236A1 (en) * 2020-05-01 2021-11-04 Cadila Healthcare Limited Pharmaceutical compositions for combination therapy
WO2021255180A1 (en) 2020-06-19 2021-12-23 Synthon B.V. Salts of bempedoic acid
US20250134841A1 (en) 2021-09-13 2025-05-01 Synthon B.V. Pharmaceutical composition of bempedoic acid
CA3256768A1 (en) 2022-05-09 2023-11-16 Renata Pharmaceutical (Ireland) Ltd PHARMACEUTICAL COMPOSITION OF BEMPEDOIC ACID
JP2024116544A (ja) * 2023-02-16 2024-08-28 株式会社三共 遊技機
JP2024116545A (ja) * 2023-02-16 2024-08-28 株式会社三共 遊技機

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101926756A (zh) * 2010-08-12 2010-12-29 北京赛科药业有限责任公司 一种氯吡格雷或其药学上可接受盐的固体制剂
US20130190354A1 (en) * 2010-10-14 2013-07-25 Novartis Ag Pharmaceutical compositions containing a dgat1 inhibitor
US20140093564A1 (en) * 2011-06-14 2014-04-03 Merck Sharp & Dohme Ltd. Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with simvastatin
WO2017023165A1 (en) * 2015-08-04 2017-02-09 Dezima Pharma B.V. Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and an atp citrate lyase inhibitor – ampk activator

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
HU230253B1 (hu) 2001-01-26 2015-11-30 Merck Sharp & Dohme Corp Peroxiszóma proliferátor-aktivált receptor (PPAR) aktivátor(ok) és szterin-abszorpció inhibitor(ok) kombinációi és alkalmazásuk vaszkuláris indikációk kezelésére
JP4438268B2 (ja) 2001-03-07 2010-03-24 大日本住友製薬株式会社 薬物顆粒の製造方法、および薬物顆粒、ならびにそれを用いた医薬製剤
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
ES2625429T3 (es) 2003-01-23 2017-07-19 Esperion Therapeutics Inc. Compuestos de hidroxilo y composiciones para el control del colesterol y utilizaciones correspondientes
AU2009292615B2 (en) * 2008-09-17 2015-12-03 Mylan Inc. Granulates, process for preparing them and pharmaceutical products containing them
JO3239B1 (ar) * 2008-09-22 2018-03-08 Novartis Ag تركيبات جالينية من مركبات عضوية
EP2168573A1 (en) * 2008-09-30 2010-03-31 LEK Pharmaceuticals D.D. Formulations comprising ezetimibe
ES2382773T3 (es) * 2009-03-13 2012-06-13 Sanovel Ilac Sanayi Ve Ticaret A.S. Composiciones de ezetimiba
CA2755274C (en) * 2009-03-13 2017-02-28 Sahoe Kakuda Tablet and granulated powder containing 6-fluoro-3-hydroxy-2-pyrazinecarboxamide
PT2459175T (pt) * 2009-07-28 2018-02-07 Egyt Gyogyszervegyeszeti Gyar Novo processo de granulação e o granulado assim preparado
EP2468258A1 (en) * 2010-12-22 2012-06-27 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient
CA2845228C (en) * 2011-08-16 2021-08-10 Baker Idi Heart & Diabetes Institute Holdings Limited Oral controlled-release formulation of 5-(pyridinyl)-2(1h)-pyridinone compounds
MX378845B (es) * 2014-01-21 2025-03-10 Bpsi Holdings Llc Revestimientos de pelicula de liberacion inmediata que contienen gliceridos de cadena media y sustratos revestidos con los mismos.
EP3267989A4 (en) 2015-03-13 2018-11-07 Esperion Therapeutics, Inc. Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
MA41793A (fr) 2015-03-16 2018-01-23 Esperion Therapeutics Inc Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
HK1257929A1 (zh) * 2015-11-06 2019-11-01 Gemphire Therapeutics Inc. 治疗混合性血脂异常

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101926756A (zh) * 2010-08-12 2010-12-29 北京赛科药业有限责任公司 一种氯吡格雷或其药学上可接受盐的固体制剂
US20130190354A1 (en) * 2010-10-14 2013-07-25 Novartis Ag Pharmaceutical compositions containing a dgat1 inhibitor
US20140093564A1 (en) * 2011-06-14 2014-04-03 Merck Sharp & Dohme Ltd. Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with simvastatin
WO2017023165A1 (en) * 2015-08-04 2017-02-09 Dezima Pharma B.V. Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and an atp citrate lyase inhibitor – ampk activator

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PAUL D. THOMPSON等: "Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance", 《JOURNAL OF CLINICAL LIPIDOLOGY》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111559961A (zh) * 2020-05-26 2020-08-21 杭州科巢生物科技有限公司 一种贝派地酸晶型及其制备方法

Also Published As

Publication number Publication date
JP7561814B2 (ja) 2024-10-04
RU2019142143A (ru) 2021-06-28
TW201900154A (zh) 2019-01-01
UA126451C2 (uk) 2022-10-05
TWI798228B (zh) 2023-04-11
AU2018272040A1 (en) 2019-12-19
JP2024178341A (ja) 2024-12-24
IL270866A (en) 2020-01-30
KR102830720B1 (ko) 2025-07-08
KR102698987B1 (ko) 2024-08-28
US20180338922A1 (en) 2018-11-29
MX2023006541A (es) 2023-06-16
JP2023022224A (ja) 2023-02-14
MX2019014122A (es) 2020-02-07
IL318957A (en) 2025-04-01
KR20250109242A (ko) 2025-07-16
PH12019502782A1 (en) 2020-10-26
KR20200032044A (ko) 2020-03-25
KR20240130156A (ko) 2024-08-28
RU2019142143A3 (https=) 2021-07-19
IL270866B2 (en) 2025-07-01
AU2024204369A1 (en) 2024-07-11
WO2018218147A1 (en) 2018-11-29
EP3630070A1 (en) 2020-04-08
BR112019024747A2 (pt) 2020-06-09
JP7187488B2 (ja) 2022-12-12
US20220249380A1 (en) 2022-08-11
IL270866B1 (en) 2025-03-01
CL2019003437A1 (es) 2020-07-10
JP2020521763A (ja) 2020-07-27
TW202400126A (zh) 2024-01-01
CA3064895A1 (en) 2018-11-29
AU2024204369B2 (en) 2025-09-11

Similar Documents

Publication Publication Date Title
JP7561814B2 (ja) 固定用量製剤
KR101380088B1 (ko) 약학 조성물
ES2325764T3 (es) Preparaciones orales con buenas caracteristicas de desintegracion.
US20250281413A1 (en) Pharmaceutical composition
CN102711761B (zh) 溶出稳定化制剂
CA3094115A1 (en) Pharmaceutical composition comprising meta arsenite and method of manufacture
CA3193661A1 (en) Pharmaceutical formulations for treating diseases mediated by kdm1a
CN105050586B (zh) 包含非晶西洛他唑的固体分散体
HK40020442A (en) Fixed dose formulations
TWI921644B (zh) 固定劑量調配物
RU2810163C2 (ru) Составы в фиксированных дозах
US20060013871A1 (en) Intimate coating of ibuprofen with poloxamers to enhance aqueous dissolution
US11260055B2 (en) Oral pharmaceutical composition of lurasidone and preparation thereof
US20240415809A1 (en) Pharmaceutical combinations
US20250345319A1 (en) Anticancer Compositions

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB03 Change of inventor or designer information
CB03 Change of inventor or designer information

Inventor after: Mohammed Abdel Nasser

Inventor after: Pratiba S. Pilgonkar

Inventor after: Arnil Kumar. S. Gandhi

Inventor before: Mohammed Abdel Nasser

Inventor before: Pratiba S. Pilgonkar

Inventor before: Anikumar Gandhi

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40020442

Country of ref document: HK